Secondary analysis of baseline data from a 4-valent HPV vaccine trial in men aged 16-27: concordant 9vHPV-type infection at 2 anogenital sites was found in 3.7% of 3363 heterosexual men vs 9.1% of 595 MSM; 8.2% of MSM had it at 3 sites.
Secondary analysisn = 3,958
Broshkevitch et al. Assessment of Concordant Human Papillomavirus Infection With 9-Valent Vaccine Types Across Anogenital Sites in Young Men